[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tang Yida\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100606623","cpet-based-hiit-for-mafld-100606623",false,"NCT07177963","CPET-based HIIT for MAFLD","Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving MAFLD","CEPHIT","Inclusion Criteria:\n\nAdults age 35\\~65 years Nonalcoholic fatty liver diagnosed by abdominal ultrasonography\n\nIn conjunction with at least one cardiometabolic risk factor:\n\n* Overweight or Obesity: ≥ 24kg\u002Fm2，or waist circumference ≥ 90 cm in men and \\> 85 cm in women, or excessive body fat mass\n* Prediabetes or type 2 diabetes mellitus: HbA1c ≥ 5.7%, or fasting plasma glucose ≥ 6.1mmol\u002FL, or 2-h plasma glucose during OGTT ≥ 7.8mmol\u002FL\n* Plasma triglycerides ≥ 1.7 mmol\u002FL (\\>-150 mg\u002Fdl) or lipid-lowering treatment\n* HDL-cholesterol ≤ -1.0 mmol\u002FL in men and ≤ -1.3 mmol\u002FL in women or lipid-lowering treatment\n* Blood pressure ≥ 130\u002F85 mmHg or treatment for hypertension\n\nExclusion Criteria:\n\n* Contraindications for Cardiopulmonary Exercise Testing\n* The electrocardiogram (ECG) results during cardiopulmonary exercise testing (CPET) showed positive findings\n* Receiving GLP-1 receptor agonists, SGLT-2i, or taking \\>2 antihypertensive\u002Fhypoglycemic\u002Flipid-lowering\u002F antiarrhythmic drugs\n* Taking dietary supplements (e.g., fish oil products, over-the-counter diet pills, meal replacements)\n* Mental illness\n* Other liver diseases\n* Movement disorder related diseases and lower limb motor injury in the past 6 months\n* Pregnant, lactating or planning to become pregnant in the near future","ALL","35 Years","65 Years",{"count":21,"type":22},54,"ESTIMATED","INTERVENTIONAL",[25],"NA","High-intensity interval training (HIIT), as an individualized exercise training mode based on cardiopulmonary exercise testing (CPET), is characterized by high-intensity training sessions interspersed with short rest periods. The findings from recent trials suggest that in the management of metabolic dysfunction-associated fatty liver disease (MAFLD), compared with traditional aerobic exercise modes such as moderate-intensity continuous training, HIIT may achieve similar or even better effects in reducing liver fat content, increasing peak oxygen uptake, improving insulin resistance, and lowering blood pressure, despite requiring less time commitment and lower energy expenditure. However, there is currently no consensus regarding the formulation of HIIT exercise protocols.\n\nBased on the lower limits of the current mainstream HIIT intensity, sets, and interval time parameters, this study aims to assess the effectiveness, safety, and feasibility of the current exercise prescription in improving MAFLD.",[28],"Metabolic Dysfunction-Associated Fatty Liver Disease",[30,31,32,33,34],"CPET","Exercise","HITT","Peak VO2","MAFLD","NOT_YET_RECRUITING","2025-09-10",{"date":38,"type":39},"2025-09-17","ACTUAL",{"date":41,"type":22},"2025-09-08",{"date":43,"type":22},"2026-04-30",{"name":45,"class":46},"Tang Yida","OTHER",5,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100447352","phase-4-cardiovascular-diseases-and-diabetes-prevention-programme-in-metabolic-syndrome-cdpp-100447352","NCT05105321","Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)","Efficacy and Safety of Berberine on Primary Prevention of Cardiovascular Diseases and Diabetes in Metabolic Syndrome: a Randomized, Controlled Trial","CDPP","Inclusion Criteria:\n\n* Patients diagnosed with metabolic syndrome aged 40-75 years old.\n* Metabolic syndrome was defined according to the Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults (revised edition 2016). Subjects will be diagnosed with metabolic syndrome when meeting three or more of the following items: 1, central obesity and\u002For abdominal obesity (waist circumference ≥90cm for men and ≥ 85cm for women); 2, hyperglycemia (fasting blood glucose ≥6.10 mmol\u002FL or two-hour blood glucose ≥7.80 mmol\u002FL in glucose tolerance test); 3, hypertension: blood pressure ≥130\u002F85 mmHg and\u002For diagnosed hypertension under treatment; 4, fasting triglyceride ≥1.7 mmol\u002FL (150mg\u002Fdl); 5, fasting HDL cholesterol\\\u003C1.0 mmol\u002FL.\n\nExclusion Criteria:\n\n* Previously diagnosed diabetes.\n* Baseline LDL cholesterol≥130mg\u002Fdl (3.4mmol\u002FL).\n* Baseline triglyceride≥500mg\u002Fdl (5.6mmol\u002FL).\n* Baseline blood pressure ≥140\u002F90 mmHg (twice not on the same day).\n* Impaired liver function, have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, alanine\u002Faspartate aminotransferase levels \\>3 times the upper limit of the reference range at the screening visit.\n* Renal dysfunction (glomerular filtration rate\\\u003C45ml\u002Fmin)\n* Patients ventilated by ventilator.\n* Hypersensitivity to berberine.\n* Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic respiratory disease).\n* Severe chronic gastrointestinal disease.\n* Severe psychiatric illness.\n* Cancer requiring treatment in past 5 years.\n* Women who are pregnant or breastfeeding .\n* Participation in another clinical trial within the past 30 days .\n* Other significant disease that in the Investigator's opinion would exclude the subject from the trial.","40 Years","75 Years",{"count":59,"type":22},5200,[61],"PHASE4","The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in China. This study aims to explore the efficacy and safety of an intervention strategy with berberine that can effectively treat a variety of risk factors (hyperglycemia, dyslipidemia, hypertension).",[64],"Metabolic Syndrome",[66,67,68,64,69],"Berberine","Cardiovascular Diseases","Diabetes","Primary Prevention","2021-11-01",{"date":72,"type":39},"2021-11-03",{"date":74,"type":22},"2021-12",{"date":76,"type":22},"2028-12",{"name":45,"class":46},1,""]